Ally Olotu

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.Bundi C Bellamy D Kibwana E Nyamako L Ogwang R Keter K Kimani D Salman AM Provstgaard-Morys S Stockdale L Hill AVS Bejon P Olotu A Hamaluba M Ewer KJ Kapulu MC
Front Immunol, (2025). 16:1620366

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu M Manda-Taylor L Balasingam S Means G Ayiro Malungu M Bejon P Chi PC Chiu C Church EC Correa-Oliveira R Day N Durbin A Egesa M Emerson C Jambo K Mathur R Metzger W Mumba N Nazziwa W Olotu A Rodgers J Sinyiza F Talaat K Kamerling I Weller C Baay M Neels P
Biologicals, (2024). 85:101747

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Cavaleri M Kaslow D Boateng E Chen WH Chiu C Choy RKM Correa-Oliveira R Durbin A Egesa M Gibani M Kapulu M Katindi M Olotu A Pongsuwan P Simuyandi M Speder B Talaat KR Weller C Wills B Baay M Balasingam S Olesen OF Neels P
Biologicals, (2024). 85:101745

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS Dicko A Tinto H Ouedraogo JB Hamaluba M Olotu A Beaumont E Ramos Lopez F Natama HM Weston S Chemba M Compaore YD Issiaka D Salou D Some AM Omenda S Lawrie A Bejon P Rao H Chandramohan D Roberts R Bharati S Stockdale L Gairola S Greenwood BM Ewer KJ Bradley J Kulkarni PS Shaligram U Hill AVS R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data.Nyandele JP Kibondo UA Issa F Van Geertruyden JP Warimwe G Jongo S Abdulla S Olotu A
PLoS One, (2023). 18:e0291244

Sporozoite immunization: innovative translational science to support the fight against malaria.Richie TL Church LWP Murshedkar T Billingsley PF James ER Chen MC Abebe Y K CN Chakravarty S Dolberg D Healy SA Diawara H Sissoko MS Sagara I Cook DM Epstein JE Mordmuller B Kapulu M Kreidenweiss A Franke-Fayard B Agnandji ST Lopez Mikue MA McCall MBB Steinhardt L Oneko M Olotu A Vaughan AM Kublin JG Murphy SC Jongo S Tanner M Sirima SB Laurens MB Daubenberger C Silva JC Lyke KE Janse CJ Roestenberg M Sauerwein RW Abdulla S Dicko A Kappe SHI Sim BKL Duffy PE Kremsner PG Hoffman SL
Expert Rev Vaccines, (2023). 22:964-1007

The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Manock SR Nsue VU Olotu A Mpina M Nyakarungu E Raso J Mtoro A Ondo Mangue ME Ntutumu Pasialo BE Nguema R Riyahi P Schindler T Daubenberger C Church LWP Billingsley PF Richie TL Abdulla S Hoffman SL
Trans R Soc Trop Med Hyg, (2022). 116:745-749

Malaria hospitalisation in East Africa: age, phenotype and transmission intensity.Kamau A Paton RS Akech S Mpimbaza A Khazenzi C Ogero M Mumo E Alegana VA Agweyu A Mturi N Mohammed S Bigogo G Audi A Kapisi J Sserwanga A Namuganga JF Kariuki S Otieno NA Nyawanda BO Olotu A Salim N Athuman T Abdulla S Mohamed AF Mtove G Reyburn H Gupta S Lourenco J Bejon P Snow RW
BMC Med, (2022). 20:28

Providing Ancillary Care in Clinical Research: A Case of Diffuse Large B-Cell Lymphoma during a Malaria Vaccine Trial in Equatorial Guinea.Manock SR Mtoro A Urbano Nsue Ndong V Olotu A Chemba M Sama Roca AE Eburi E Garcia GA Cortes Falla C Niemczura de Carvalho J Contreras J Saturno B Riocalo JD Nze Mba JL Koka R Lee ST Menon H Church LWP Ayekaba MO Billingsley PF Abdulla S Richie TL Hoffman SL
Am J Trop Med Hyg, (2020). 104:695-699

The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa.Billingsley PF Maas CD Olotu A Schwabe C Garcia GA Rivas MR Hergott DEB Daubenberger C Saverino E Chaouch A Embon O Chemba M Nyakarungu E Hamad A Cortes C Schindler T Mpina M Mtoro A Sim BKL Richie TL McGhee K Tanner M Obiang Lima GM Abdulla S Hoffman SL Ayekaba MO
Am J Trop Med Hyg, (2020). 103:947-954

Detection of malaria parasites in dried human blood spots using mid-infrared spectroscopy and logistic regression analysis.Mwanga EP Minja EG Mrimi E Jimenez MG Swai JK Abbasi S Ngowo HS Siria DJ Mapua S Stica C Maia MF Olotu A Sikulu-Lord MT Baldini F Ferguson HM Wynne K Selvaraj P Babayan SA Okumu FO
Malar J, (2019). 18:341

High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria.Offeddu V Olotu A Osier F Marsh K Matuschewski K Thathy V
Front Immunol, (2017). 8:488

Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study.Gitaka J Ogwang C Ngari M Akoo P Olotu A Kerubo C Fegan G Njuguna P Nyakaya G Otieno T Mwambingu G Awuondo K Lowe B Chilengi R Berkley JA
PLoS One, (2017). 12:e0177382

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.Olotu A Fegan G Wambua J Nyangweso G Leach A Lievens M Kaslow DC Njuguna P Marsh K Bejon P
N Engl J Med, (2016). 374:2519-29

Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.Rono J Farnert A Murungi L Ojal J Kamuyu G Guleid F Nyangweso G Wambua J Kitsao B Olotu A Marsh K Osier FH
BMC Med, (2015). 13:114

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.Olotu A Clement F Jongert E Vekemans J Njuguna P Ndungu FM Marsh K Leroux-Roels G Bejon P
PLoS One, (2014). 9:e115126

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.White MT Bejon P Olotu A Griffin JT Bojang K Lusingu J Salim N Abdulla S Otsyula N Agnandji ST Lell B Asante KP Owusu-Agyei S Mahama E Agbenyega T Ansong D Sacarlal J Aponte JJ Ghani AC
BMC Med, (2014). 12:117

CD4+ T cell responses to the Plasmodium falciparum erythrocyte membrane protein 1 in children with mild malaria.Gitau EN Tuju J Karanja H Stevenson L Requena P Kimani E Olotu A Kimani D Marsh K Bull P Urban BC
J Immunol, (2014). 192:1753-61

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Warimwe GM Fletcher HA Olotu A Agnandji ST Hill AV Marsh K Bejon P
BMC Med, (2013). 11:184

The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection.White MT Bejon P Olotu A Griffin JT Riley EM Kester KE Ockenhouse CF Ghani AC
PLoS One, (2013). 8:e61395